Executive Summary
Today's insider trading pulse reveals a pronounced bearish tilt, with 11 filings showing negative sentiment from direct sales by senior executives, including C-suite officers at Aktis Oncology, Tempus AI, JFrog, and Insmed. A notable cluster of option exercises paired with immediate stock sales—particularly at Aktis Oncology and Insmed—suggests opportunistic profit-taking rather than a loss of confidence in the business.
In contrast, the data shows a significant volume of neutral insider activity, primarily director stock awards and option grants at Planet Labs PBC and Seres Therapeutics, indicating routine compensation rather than conviction buying. A single positive signal stands out: a $40 million debt purchase by a 10% owner at Angel Oak Financial Strategies Income Term Trust, implying strong institutional confidence. Period-over-period comparisons were not available in the filings, limiting trend analysis, but the aggregate insider selling value exceeds $10 million, concentrated in healthcare and technology. The absence of forward-looking guidance or capital allocation changes in the filings suggests a quiet period for most companies, making the insider sales the primary actionable signal.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Form 4
Tracking the trend? Catch up on the prior USA Insider Trading Pulse digest from July 09, 2026.
Investment Signals (11)
- Aktis Oncology ↓ (BEARISH)▲
COO and CMO collectively sold ~$1.7M in stock after exercising cheap options ($3.66-$4.95 strike vs $27.94 market), a classic 'exercise-and-sell' pattern that reduces personal exposure. With only 4,200 and 4,371 shares retained respectively, insider ownership is minimal post-sale.
- Tempus AI ↓ (BEARISH)▲
CEO Fukushima Ryan sold $1.78M in stock across 4 transactions at ~$57, all under a Rule 10b5-1 plan. While pre-planned, the scale (13,984 shares in one day) and proximity to the IPO lockup expiry (if applicable) warrant monitoring for further dilution.
- JFrog Ltd ↓ (BEARISH)▲
CEO Shlomi Ben Haim sold $1.42M in stock at ~$94.72, retaining 4.58M shares (a 99.8%+ holding). The sale is small relative to his total stake, but the use of a 10b5-1 plan suggests a pre-determined strategy.
- Insmed Inc ↓ (BEARISH)▲
Chair & CEO Lewis William sold $583K after exercising options at $30.46 and $17.16 (deep in-the-money). He retains 259K shares, but the pattern of selling immediately after exercise signals a desire to monetize gains.
- Casey's General Stores (BEARISH)▲
CFO Bramlage sold $4.78M in a single transaction at $838.16, retaining only 29,677 shares. This is a large, unscheduled sale (no 10b5-1 plan noted) that could signal a lack of confidence or personal liquidity needs.
- Hormel Foods ↓ (BEARISH)▲
Director Bhojwani sold $495K at $24.51, a 39% reduction in his stake (from 52,202 to 32,002 shares). This is a significant insider reduction for a consumer staples company, often a cautionary signal.
- Semtech Corp ↓ (BEARISH)▲
EVP & COO Silberstein sold $436K across 6 transactions at ~$125-130 under a 10b5-1 plan. The sale is moderate relative to his 96,862 remaining shares, but the multiple transactions suggest a systematic reduction.
-
10% owner MetLife Investment Management bought $40M in Series C senior unsecured notes (5.364% due 2030). This large institutional debt purchase signals strong credit confidence and a yield pickup.
- Sea Ltd ↓ (BEARISH)▲
COO Ye Gang sold $1.07M and CCO Wang Yanjun sold $58.9K, both under 10b5-1 plans. The COO's sale is more material (6/10), but the plans reduce signaling value.
-
Director Malcolm sold $179K at $550.59 after exercising 650 RSUs. The sale is small, but the exercise-and-sell pattern is consistent with tax planning. [NEUTRAL/BEARISH]
- Domino's Pizza▲
EVP Garcia sold $145K after exercising options at $136.89 (vs $297 market). The sale is small relative to her 9,352 remaining shares, but the pattern is notable. [NEUTRAL/BEARISH]
Risk Flags (8)
- Aktis Oncology - Insider Exodus↓ [HIGH RISK]▼
Both the COO and CMO sold nearly all their exercisable shares, retaining only 4,200 and 4,371 shares respectively. This near-total liquidation by two top executives is a major red flag for a clinical-stage biotech.
- Casey's General Stores - CFO Single Large Sale [HIGH RISK]▼
The CFO's $4.78M sale with no 10b5-1 plan and no option exercise suggests a discretionary decision. For a stable retailer, such a large unplanned sale by the CFO is unusual.
- Hormel Foods - Director Stake Reduction↓ [MEDIUM RISK]▼
Director Bhojwani cut his stake by 39% in a single transaction. For a dividend-paying consumer staple, this level of insider selling is a potential signal of concern about near-term performance.
- Tempus AI - CEO Selling at IPO+ Stage↓ [MEDIUM RISK]▼
CEO Fukushima sold $1.78M in a single day. If the company is still in its post-IPO quiet period, this could signal that insiders view the current valuation as full.
- Insmed Inc - CEO Exercise-and-Sell↓ [MEDIUM RISK]▼
The CEO exercised deeply in-the-money options ($17-$30 strike) and sold immediately at $116.55. While common, the scale ($583K) and the fact that he sold more than he exercised (5,005 sold vs 10,699 exercised) indicates net share reduction.
- Sea Ltd - COO Systematic Selling↓ [MEDIUM RISK]▼
COO Ye Gang sold $1.07M across 10 transactions. While under a 10b5-1 plan, the consistent selling pattern over multiple days at varying prices suggests a deliberate reduction.
- Semtech Corp - EVP Multiple Sales↓ [LOW-MEDIUM RISK]▼
EVP & COO Silberstein sold across 6 transactions in a short period. The use of a 10b5-1 plan reduces alarm, but the frequency is notable.
- Domino's Pizza - Tax Withholding Sales [LOW RISK]▼
Two EVPs had shares withheld for taxes ($69K and $22K). While routine, the fact that they didn't cover taxes with cash could indicate cash constraints.
Opportunities (8)
- ◆
MetLife's $40M purchase of 5.364% senior notes due 2030 is a strong signal from a sophisticated fixed-income investor. The yield is attractive in the current rate environment, and the purchase size is large relative to the trust's market cap.
- Planet Labs PBC - Director Accumulation↓ (OPPORTUNITY)◆
Six directors were awarded 6,479 shares each (total ~38,874 shares) as part of routine compensation. While not a purchase, the consistent awards signal board alignment and commitment. The stock may be undervalued if the space-imaging business gains traction.
- Seres Therapeutics - Option Grants to Board↓ (OPPORTUNITY)◆
Five directors and officers were awarded stock options (6,500-50,000 each), aligning incentives with long-term performance. For a clinical-stage biotech, option grants are a positive signal that the board is committed to the pipeline.
- JFrog Ltd - CEO Retains 99.8% Stake↓ (OPPORTUNITY)◆
Despite selling $1.42M, CEO Shlomi Ben Haim still holds 4.58M shares. His massive retained ownership aligns him with shareholders and suggests the sale is for diversification, not a lack of faith.
- Maris Tech Ltd - Insider Awards↓ (OPPORTUNITY)◆
Three insiders (CFO and two others) were awarded 125,951 and 88,451 ordinary shares respectively. These are significant awards for a small-cap tech company, signaling strong insider alignment.
- Ally Financial - Director Awards↓ (OPPORTUNITY)◆
Two directors were awarded 1,034 and 300 shares respectively at $45.95. While small, these awards indicate board commitment. Ally's current valuation may offer a buying opportunity if the consumer credit cycle stabilizes.
- Lowe's Companies - Phantom Stock Awards (OPPORTUNITY)◆
Two directors were awarded phantom stock (258 and 70 units) at $213.00. Phantom stock aligns directors with shareholder value without diluting equity. Lowe's is a strong cash-flow generator.
-
CFO Lee had 4,698 shares withheld for taxes ($897K). This is a routine transaction, but the fact that he retained 36,736 shares suggests no desire to reduce his stake. [NEUTRAL/OPPORTUNITY]
Sector Themes (5)
- Biotech Insider Profit-Taking (BEARISH)◆
Aktis Oncology and Insmed both saw top executives exercise cheap options and immediately sell shares. This pattern is common in biotech after positive trial results or stock appreciation, but the near-total liquidation at Aktis is extreme. Investors should watch for further insider sales as a leading indicator of sentiment.
- Tech Insider Selling Under 10b5-1 Plans (BEARISH)◆
Sea Ltd, Semtech, Tempus AI, and JFrog all had insider sales under Rule 10b5-1 plans. While these plans reduce signaling value, the aggregate selling pressure (~$4.3M) in tech is notable. Investors should monitor if this trend broadens.
- Director Compensation via Stock Awards (NEUTRAL)◆
Multiple companies (Planet Labs, Seres Therapeutics, Ally Financial, Lowe's) awarded stock to directors. This is standard practice, but the volume at Planet Labs (6 directors awarded shares) suggests a concerted effort to align the board.
- Consumer Staples Insider Selling (BEARISH)◆
Hormel Foods (director sold $495K) and Casey's General Stores (CFO sold $4.78M) saw notable insider sales. For defensive sectors, insider selling can be a contrarian signal if valuations are stretched.
- Small-Cap Insider Awards◆
Maris Tech and Newton Golf Company awarded significant equity to insiders (125K shares and $515K in preferred stock respectively). These awards are large relative to company size and suggest a focus on retention and alignment. [NEUTRAL/POSITIVE]
Watch List (8)
-
Watch for additional insider sales or a change in the COO/CMO's remaining holdings. If they sell their remaining 4,200/4,371 shares, it would be a strong negative signal. Next catalyst: clinical trial data readout.
- Casey's General Stores👁
Monitor for any 8-K filing or earnings pre-announcement following the CFO's large sale. The next earnings call (expected late August 2026) will be key to assess fundamentals.
-
Watch for further CEO sales or lockup expirations. The next insider trading report will reveal if the selling continues. Earnings call (expected August 2026) will provide guidance on AI adoption.
-
Monitor CEO Lewis William's remaining 259K shares. If he continues to sell, it could signal a peak in sentiment. The next FDA decision or trial update is a key catalyst.
-
Track the performance of the 5.364% Series C notes. MetLife's $40M purchase is a strong vote of confidence; any further insider buying would be bullish.
-
Watch for any insider purchases following the director awards. The next earnings report (expected September 2026) will show if the space-imaging business is gaining traction.
-
Monitor CEO Shlomi Ben Haim's selling pattern. If he continues to sell under the 10b5-1 plan, it could indicate a planned reduction. The next earnings call (expected August 2026) will provide guidance.
-
Watch for additional director sales. If other insiders follow, it could signal broader concern. The next earnings report (expected August 2026) will be critical for the consumer staples sector.
Filing Analyses
(50)
10-07-2026
Chief Operating Officer Ron-Bigger Shulamit sold 30,000 Common Stock at $27.94 (~$838K). 5 transactions reported in total. Ron-Bigger Shulamit holds 4,200 shares after the transaction.
- · Chief Operating Officer Ron-Bigger Shulamit exercised/converted 50,000 Common Stock at $3.66 (~$183K)
- · Chief Operating Officer Ron-Bigger Shulamit sold 15,800 Common Stock at $27.13 (~$429K)
- · Chief Operating Officer Ron-Bigger Shulamit sold 30,000 Common Stock at $27.94 (~$838K)
- · Chief Operating Officer Ron-Bigger Shulamit sold 4,200 Common Stock at $28.75 (~$121K)
- · Chief Operating Officer Ron-Bigger Shulamit exercised/converted 50,000 Stock Option (Right to Buy)
10-07-2026
Chief Medical Officer Czibere Akos sold 30,829 Common Stock at $27.95 (~$862K). 5 transactions reported in total. Czibere Akos holds 4,371 shares after the transaction.
- · Chief Medical Officer Czibere Akos exercised/converted 50,000 Common Stock at $4.95 (~$248K)
- · Chief Medical Officer Czibere Akos sold 14,800 Common Stock at $27.13 (~$401K)
- · Chief Medical Officer Czibere Akos sold 30,829 Common Stock at $27.95 (~$862K)
- · Chief Medical Officer Czibere Akos sold 4,371 Common Stock at $28.71 (~$125K)
- · Chief Medical Officer Czibere Akos exercised/converted 50,000 Stock Option (Right to Buy)
10-07-2026
CCO and GC Wang Yanjun sold 547 Class A ordinary shares at $107.71 (~$58.9K). 10 transactions reported in total. Wang Yanjun holds 40,000 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · CCO and GC Wang Yanjun sold 390 Class A ordinary shares at $102.09 (~$39.8K)
- · CCO and GC Wang Yanjun sold 331 Class A ordinary shares at $102.99 (~$34.1K)
- · CCO and GC Wang Yanjun sold 60 Class A ordinary shares at $104.35 (~$6.26K)
- · CCO and GC Wang Yanjun sold 418 Class A ordinary shares at $105.13 (~$43.9K)
- · CCO and GC Wang Yanjun sold 1 Class A ordinary shares at $105.80 (~$106)
- · CCO and GC Wang Yanjun sold 93 Class A ordinary shares at $105.53 (~$9.81K)
- · CCO and GC Wang Yanjun sold 73 Class A ordinary shares at $106.51 (~$7.78K)
- · CCO and GC Wang Yanjun sold 547 Class A ordinary shares at $107.71 (~$58.9K)
10-07-2026
COO Ye Gang sold 9,900 Class A ordinary shares at $107.83 (~$1.07M). 10 transactions reported in total. Ye Gang holds 440,000 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · COO Ye Gang sold 8,000 Class A ordinary shares at $101.84 (~$815K)
- · COO Ye Gang sold 6,600 Class A ordinary shares at $102.77 (~$678K)
- · COO Ye Gang sold 500 Class A ordinary shares at $103.74 (~$51.9K)
- · COO Ye Gang sold 3,818 Class A ordinary shares at $105.02 (~$401K)
- · COO Ye Gang sold 1,082 Class A ordinary shares at $105.52 (~$114K)
- · COO Ye Gang sold 800 Class A ordinary shares at $105.66 (~$84.5K)
- · COO Ye Gang sold 1,100 Class A ordinary shares at $106.72 (~$117K)
- · COO Ye Gang sold 9,900 Class A ordinary shares at $107.83 (~$1.07M)
10-07-2026
Director Lawrence Scott D exercised/converted 1,800 Common Stock at $11.86 (~$21.3K). Lawrence Scott D holds 77,092 shares after the transaction.
- · Director Lawrence Scott D exercised/converted 1,800 Common Stock at $11.86 (~$21.3K)
- · Director Lawrence Scott D exercised/converted 1,800 Stock Option (Right to Buy)
10-07-2026
President Emery Christina acquired 43.3107 Barings Non-Qualified Thrift Plan at $17.35 (~$751).
- · President Emery Christina acquired 43.3107 Barings Non-Qualified Thrift Plan at $17.35 (~$751)
10-07-2026
10% owner BANK OF AMERICA CORP /DE/ reported beneficial ownership in Bluejay Diagnostics, Inc.. No securities are beneficially owned.
10-07-2026
Chief Financial Officer Bramlage Stephen P JR sold 5,700 Common Stock at $838.16 (~$4.78M). Bramlage Stephen P JR holds 29,677 shares after the transaction.
- · Chief Financial Officer Bramlage Stephen P JR sold 5,700 Common Stock at $838.16 (~$4.78M)
10-07-2026
Director Carden Mark exercised/converted 50,000 Common Stock at $0.72 (~$36K). Carden Mark holds 110,980 shares after the transaction.
- · Director Carden Mark exercised/converted 50,000 Common Stock at $0.72 (~$36K)
- · Director Carden Mark exercised/converted 50,000 Stock Option at $0.72 (~$36K)
10-07-2026
10% owner MetLife Investment Management, LLC bought 40,000,000 5.364% Series C Senior Unsecured Notes due July 8, 2030 at $40,000,000.00 (~$1600T).
- · 10% owner MetLife Investment Management, LLC bought 40,000,000 5.364% Series C Senior Unsecured Notes due July 8, 2030 at $40,000,000.00 (~$1600T)
10-07-2026
Chief Operating Officer Tappan Moore III sold 472 Common Stock at $18.65 (~$8.8K). Tappan Moore III holds 12,869 shares after the transaction.
- · Chief Operating Officer Tappan Moore III sold 472 Common Stock at $18.65 (~$8.8K)
10-07-2026
Director Kim Vyacheslav sold 6,491 American Depositary Shares, no par value at $87.35 (~$567K). 4 transactions reported in total. Trades executed under a Rule 10b5-1 plan.
- · Director Kim Vyacheslav sold 6,491 American Depositary Shares, no par value at $87.35 (~$567K)
- · Director Kim Vyacheslav sold 1,215 American Depositary Shares, no par value at $87.82 (~$107K)
- · Director Kim Vyacheslav sold 2,934 American Depositary Shares, no par value at $87.50 (~$257K)
- · Director Kim Vyacheslav sold 4,149 American Depositary Shares, no par value at $88.61 (~$368K)
10-07-2026
Director Masters Blake was awarded 258,929 Class A Common Stock, par value $0.0001 per share. Masters Blake holds 442,827 shares after the transaction.
- · Director Masters Blake was awarded 258,929 Class A Common Stock, par value $0.0001 per share
10-07-2026
Director PERCEPTIVE ADVISORS LLC was awarded 28,000 Stock Option (Right to Buy).
- · Director PERCEPTIVE ADVISORS LLC was awarded 28,000 Stock Option (Right to Buy)
10-07-2026
EVP and COO Silberstein Asaf sold 3,354 Common Stock at $129.94 (~$436K). 6 transactions reported in total. Silberstein Asaf holds 96,862 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · EVP and COO Silberstein Asaf sold 437 Common Stock at $124.19 (~$54.3K)
- · EVP and COO Silberstein Asaf sold 2,448 Common Stock at $125.18 (~$306K)
- · EVP and COO Silberstein Asaf sold 273 Common Stock at $126.60 (~$34.6K)
- · EVP and COO Silberstein Asaf sold 588 Common Stock at $127.61 (~$75K)
- · EVP and COO Silberstein Asaf sold 1,400 Common Stock at $128.70 (~$180K)
- · EVP and COO Silberstein Asaf sold 3,354 Common Stock at $129.94 (~$436K)
10-07-2026
EVP, Chief HR Officer PITTENGER MAUREEN had withheld for taxes 229 Common Stock, $0.01 par value at $302.35 (~$69.2K). PITTENGER MAUREEN holds 3,289.265 shares after the transaction.
- · EVP, Chief HR Officer PITTENGER MAUREEN had withheld for taxes 229 Common Stock, $0.01 par value at $302.35 (~$69.2K)
10-07-2026
10% owner AEROEQUITY GP, LLC was awarded 2,289,366 Common Stock, par value $0.0001 per share at $34.00 (~$77.8M). AEROEQUITY GP, LLC holds 32,915,588 shares after the transaction.
- · 10% owner AEROEQUITY GP, LLC was awarded 2,289,366 Common Stock, par value $0.0001 per share at $34.00 (~$77.8M)
10-07-2026
EVP, Chief Tech & Data Ofcr GARCIA KELLY E sold 487 Common Stock, $0.01 par value at $297.01 (~$145K). GARCIA KELLY E holds 9,351.818 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · EVP, Chief Tech & Data Ofcr GARCIA KELLY E exercised/converted 487 Common Stock, $0.01 par value at $136.89 (~$66.7K)
- · EVP, Chief Tech & Data Ofcr GARCIA KELLY E sold 487 Common Stock, $0.01 par value at $297.01 (~$145K)
- · EVP, Chief Tech & Data Ofcr GARCIA KELLY E exercised/converted 487 Option to Purchase Common Stock
10-07-2026
SVP Chief Supply Chain Officer Arends Mitchell Andrew was awarded 3,843 Common Stock. Arends Mitchell Andrew holds 3,843 shares after the transaction.
- · SVP Chief Supply Chain Officer Arends Mitchell Andrew was awarded 3,843 Common Stock
10-07-2026
Chief Financial Officer Lee Damon J. had withheld for taxes 4,698 Common Stock at $190.95 (~$897K). Lee Damon J. holds 36,736 shares after the transaction.
- · Chief Financial Officer Lee Damon J. had withheld for taxes 4,698 Common Stock at $190.95 (~$897K)
10-07-2026
Director Deeter Byron B sold 0 Class A Common Stock.
- · Director Deeter Byron B sold 0 Class A Common Stock
- · Director Deeter Byron B sold 0 Class A Common Stock
10-07-2026
Director Bhojwani Gary C. sold 20,200 Common Stock at $24.51 (~$495K). Bhojwani Gary C. holds 32,002 shares after the transaction.
- · Director Bhojwani Gary C. sold 20,200 Common Stock at $24.51 (~$495K)
10-07-2026
Chair and CEO Lewis William sold 5,005 Common Stock at $116.55 (~$583K). 7 transactions reported in total. Lewis William holds 259,058 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Chair and CEO Lewis William exercised/converted 6,259 Common Stock at $30.46 (~$191K)
- · Chair and CEO Lewis William exercised/converted 4,440 Common Stock at $17.16 (~$76.2K)
- · Chair and CEO Lewis William sold 5,005 Common Stock at $116.55 (~$583K)
- · Chair and CEO Lewis William sold 2,335 Common Stock at $117.62 (~$275K)
- · Chair and CEO Lewis William sold 3,359 Common Stock at $118.52 (~$398K)
- · Chair and CEO Lewis William exercised/converted 6,259 Stock Option (right to buy)
- · Chair and CEO Lewis William exercised/converted 4,440 Stock Option (right to buy)
10-07-2026
Bastiker Carmela was awarded 125,951 Ordinary shares. Bastiker Carmela holds 125,951 shares after the transaction.
- · Bastiker Carmela was awarded 125,951 Ordinary shares
10-07-2026
Malka Hananya was awarded 88,451 Ordinary shares. Malka Hananya holds 88,451 shares after the transaction.
- · Malka Hananya was awarded 88,451 Ordinary shares
10-07-2026
Chief Financial Officer Bussy Nir was awarded 125,951 Ordinary shares. Bussy Nir holds 125,951 shares after the transaction.
- · Chief Financial Officer Bussy Nir was awarded 125,951 Ordinary shares
10-07-2026
Director MALCOLM JAN sold 325 Common Stock at $550.59 (~$179K). MALCOLM JAN holds 450 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Director MALCOLM JAN exercised/converted 650 Common Stock
- · Director MALCOLM JAN sold 325 Common Stock at $550.59 (~$179K)
- · Director MALCOLM JAN exercised/converted 650 Restricted Stock Unit
10-07-2026
Director Raymond John w was awarded 6,479 Class A Common Stock. Raymond John w holds 50,087 shares after the transaction.
- · Director Raymond John w was awarded 6,479 Class A Common Stock
10-07-2026
Director DREILING RICHARD W was awarded 258.216 Phantom Stock at $213.00 (~$55K).
- · Director DREILING RICHARD W was awarded 258.216 Phantom Stock at $213.00 (~$55K)
10-07-2026
Director GIBBONS THOMAS P was awarded 1,034 Common Stock at $45.95 (~$47.5K). GIBBONS THOMAS P holds 26,062 shares after the transaction.
- · Director GIBBONS THOMAS P was awarded 1,034 Common Stock at $45.95 (~$47.5K)
10-07-2026
Director Reese Scott was awarded 6,479 Class A Common Stock. Reese Scott holds 17,446 shares after the transaction.
- · Director Reese Scott was awarded 6,479 Class A Common Stock
- · Director Reese Scott was awarded 2,160 Class A Common Stock
10-07-2026
Director Hoge Brett Widney was awarded 3,246.66 Series A Convertible Preferred Stock at $95.24 (~$309K).
- · Director Hoge Brett Widney was awarded 3,246.66 Series A Convertible Preferred Stock at $95.24 (~$309K)
- · Director Hoge Brett Widney was awarded 2,164.44 Series A Convertible Preferred Stock at $95.24 (~$206K)
10-07-2026
Director Bright Gunther was awarded 300 Common Stock at $45.95 (~$13.8K). Bright Gunther holds 6,466 shares after the transaction.
- · Director Bright Gunther was awarded 300 Common Stock at $45.95 (~$13.8K)
10-07-2026
Director Gadde Vijaya was awarded 6,479 Class A Common Stock. Gadde Vijaya holds 256,648 shares after the transaction.
- · Director Gadde Vijaya was awarded 6,479 Class A Common Stock
10-07-2026
Director Backstrom Jay T. was awarded 1,447 Common stock. Backstrom Jay T. holds 1,447 shares after the transaction.
- · Director Backstrom Jay T. was awarded 1,447 Common stock
- · Director Backstrom Jay T. exercised/converted 1,447 Restricted stock units
10-07-2026
Director DOUGLAS LAURIE Z was awarded 70.423 Phantom Stock at $213.00 (~$15K).
- · Director DOUGLAS LAURIE Z was awarded 70.423 Phantom Stock at $213.00 (~$15K)
10-07-2026
EVP, CHIEF COMMERCIAL OFFICER Fiore Michael Henry had withheld for taxes 2,045 Common Stock at $95.08 (~$194K). Fiore Michael Henry holds 54,598 shares after the transaction.
- · EVP, CHIEF COMMERCIAL OFFICER Fiore Michael Henry had withheld for taxes 2,045 Common Stock at $95.08 (~$194K)
10-07-2026
Chief Legal Officer Shaman David R. had withheld for taxes 704 Class B Common Stock at $31.65 (~$22.3K). Shaman David R. holds 629,731 shares after the transaction.
- · Chief Legal Officer Shaman David R. had withheld for taxes 704 Class B Common Stock at $31.65 (~$22.3K)
10-07-2026
Director BASS CARL was awarded 6,479 Class A Common Stock. BASS CARL holds 406,545 shares after the transaction.
- · Director BASS CARL was awarded 6,479 Class A Common Stock
- · Director BASS CARL was awarded 2,880 Class A Common Stock
10-07-2026
Director Brennan Ita M was awarded 6,479 Class A Common Stock. Brennan Ita M holds 261,873 shares after the transaction.
- · Director Brennan Ita M was awarded 6,479 Class A Common Stock
- · Director Brennan Ita M was awarded 2,736 Class A Common Stock
10-07-2026
President & CEO Flees Lori Ann was awarded 25 Deferred Stock Units at $37.98 (~$950).
- · President & CEO Flees Lori Ann was awarded 25 Deferred Stock Units at $37.98 (~$950)
10-07-2026
CEO, Data Fukushima Ryan sold 13,984 Class A Common Stock at $56.80 (~$794K). 4 transactions reported in total. Fukushima Ryan holds 167,763 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · CEO, Data Fukushima Ryan sold 13,984 Class A Common Stock at $56.80 (~$794K)
- · CEO, Data Fukushima Ryan sold 13,686 Class A Common Stock at $57.37 (~$785K)
- · CEO, Data Fukushima Ryan sold 3,477 Class A Common Stock at $58.55 (~$204K)
- · CEO, Data Fukushima Ryan sold 2,137 Class A Common Stock at $59.47 (~$127K)
10-07-2026
Director Graves Kurt was awarded 6,500 Stock Option (right to buy).
- · Director Graves Kurt was awarded 6,500 Stock Option (right to buy)
10-07-2026
Chief Operating Officer Gloria Melanie sold 1,930 Common Stock at $39.53 (~$76.3K). Gloria Melanie holds 222,357 shares after the transaction.
- · Chief Operating Officer Gloria Melanie sold 1,930 Common Stock at $39.53 (~$76.3K)
- · Chief Operating Officer Gloria Melanie sold 106 Common Stock at $39.99 (~$4.24K)
10-07-2026
See Remarks Kender Richard N was awarded 50,000 Stock Option (right to buy).
- · See Remarks Kender Richard N was awarded 50,000 Stock Option (right to buy)
10-07-2026
CHIEF EXECUTIVE OFFICER Shlomi Ben Haim sold 7,755 Ordinary Shares at $94.72 (~$735K). Shlomi Ben Haim holds 4,577,237 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · CHIEF EXECUTIVE OFFICER Shlomi Ben Haim sold 5,845 Ordinary Shares at $93.65 (~$547K)
- · CHIEF EXECUTIVE OFFICER Shlomi Ben Haim sold 7,755 Ordinary Shares at $94.72 (~$735K)
- · CHIEF EXECUTIVE OFFICER Shlomi Ben Haim sold 1,400 Ordinary Shares at $95.42 (~$134K)
10-07-2026
See Remarks Thorell Marella was awarded 7,500 Stock Option (right to buy).
- · See Remarks Thorell Marella was awarded 7,500 Stock Option (right to buy)
10-07-2026
Director Fraser Claire was awarded 6,500 Stock Option (right to buy).
- · Director Fraser Claire was awarded 6,500 Stock Option (right to buy)
10-07-2026
Director Dere Willard H was awarded 6,500 Stock Option (right to buy).
- · Director Dere Willard H was awarded 6,500 Stock Option (right to buy)
10-07-2026
Director Ausiello Dennis A was awarded 6,500 Stock Option (right to buy).
- · Director Ausiello Dennis A was awarded 6,500 Stock Option (right to buy)
Get daily alerts with 11 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 50 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: USA Insider Trading Pulse
🇺🇸 More from United States
View all →July 13, 2026
US Pre-Market SEC Filings Roundup — July 13, 2026
US Pre-Market SEC Filings Roundup
July 12, 2026
General Federal Contracts — July 12, 2026
General Federal Contracts
July 12, 2026
High-Value Federal Grants ($5M+) — July 12, 2026
High-Value Federal Grants ($5M+)
July 12, 2026
Mega Contracts Monitor ($100M+) — July 12, 2026
Mega Contracts Monitor ($100M+)